Cyclopropyl amide derivatives

Details Cyclopropyl amide derivatives Cyclopropyl amide derivatives

2008-08-21

2011-11-22

McKane, Joseph K. (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

Reexamination Certificate

active

08063215

ABSTRACT:
Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.

REFERENCES:
patent: 3331830 (1967-07-01), Tomcufcik et al.
patent: 3449427 (1969-06-01), Kaiser et al.
patent: 3686335 (1972-08-01), Kaiser et al.
patent: 4547505 (1985-10-01), Oepen et al.
patent: 5112818 (1992-05-01), Nakagawa et al.
patent: 6284761 (2001-09-01), Zhang et al.
patent: 6521619 (2003-02-01), Link et al.
patent: 6544996 (2003-04-01), Zhang et al.
patent: 6861432 (2005-03-01), Cleve et al.
patent: 7053089 (2006-05-01), Claiborne et al.
patent: 7217716 (2007-05-01), Claiborne et al.
patent: 2004/0077618 (2004-04-01), Bennani et al.
patent: 2004/0209858 (2004-10-01), Bennani et al.
patent: 2007/0167436 (2007-07-01), Nettekoven et al.
patent: 2008/0021081 (2008-01-01), Liu et al.
patent: 2008/0242653 (2008-10-01), Liu et al.
patent: 2010/0216812 (2010-08-01), Griffin
patent: 3418167 (1985-11-01), None
patent: 3600288 (1987-07-01), None
patent: 3618004 (1987-12-01), None
patent: 0234036 (1987-09-01), None
patent: 1086192 (1967-10-01), None
patent: 1297727 (1987-03-01), None
patent: 3306 (2007-03-01), None
patent: 9109594 (1991-07-01), None
patent: 9303615 (1993-03-01), None
patent: 9616040 (1996-05-01), None
patent: 9637469 (1996-11-01), None
patent: 9833784 (1998-08-01), None
patent: 9837077 (1998-08-01), None
patent: 9937304 (1999-07-01), None
patent: 9942107 (1999-08-01), None
patent: 0040572 (2000-07-01), None
patent: 0122963 (2001-04-01), None
patent: 0202522 (2002-01-01), None
patent: 0208221 (2002-01-01), None
patent: 02068409 (2002-09-01), None
patent: 2003004480 (2003-01-01), None
patent: 03103666 (2003-12-01), None
patent: 2004037769 (2004-05-01), None
patent: 2004046110 (2004-06-01), None
patent: 2004055010 (2004-07-01), None
patent: 2004099156 (2004-11-01), None
patent: WO 2005/028475 (2005-03-01), None
patent: 2006014168 (2006-02-01), None
patent: 2006040192 (2006-04-01), None
patent: 2006071730 (2006-07-01), None
patent: 2006079916 (2006-08-01), None
patent: 2006088075 (2006-08-01), None
patent: 2006100591 (2006-09-01), None
patent: 2006103544 (2006-10-01), None
patent: 2006103545 (2006-10-01), None
patent: 2006103555 (2006-10-01), None
patent: 2007011623 (2007-01-01), None
patent: 2007016496 (2007-02-01), None
patent: 2007049123 (2007-05-01), None
patent: 2007053386 (2007-05-01), None
patent: 2007075895 (2007-07-01), None
patent: 2007076140 (2007-07-01), None
patent: 2007098536 (2007-09-01), None
patent: 2007111921 (2007-10-01), None
patent: 2007150010 (2007-12-01), None
patent: 2008003702 (2008-01-01), None
patent: 2008024284 (2008-02-01), None
patent: 2008147864 (2008-12-01), None
patent: 2008150364 (2008-12-01), None
patent: 2010096011 (2010-08-01), None
Berlin et al., “Recent advances in the development of histamine H3 antagonists,” Expert Opin. Ther. Patents, 2007, vol. 17(6), pp. 675-687.
De Esch et al., “Development of a pharmacophore model for histamine H3 receptor antagonists, using the newly developed molecular modeling program SLATE,” J. Med. Chem., 2001, vol. 44, pp. 1666-1674.
Letavic et al., “Recent medicinal chemistry of the histamine H3 receptor,” Progress in Medicinal Chemistry, 2006, vol. 44, pp. 181-206.
Mills et al., “SLATE: A method for the superposition of flexible ligands,” Journal of Computer-Aided Molecular Design, 2001, vol. 15, pp. 81-96.
Sander et al., “Histamine H3 Receptor Antagonists to Clinics,” Biol. Pharm. Bull., 2008, vol. 31(12), pp. 2163-2181.
Watanabe, Mizuki et al., Poster “Development of potent histamine H3/H4 receptor ligands by the stereochemical diversity-oriented chiral cyclopropane-based conformational restriction strategy,” Presented at 234th ACS National Meeting held in Boston Aug. 19-23, 2007.
Wijtmans et al., “Histamine H3 receptor ligands break ground in a remarkable plethora of therapeutic areas,” Expert Opin. Investig. Drugs, 2007, vol. 16(7), pp. 967-985.
Yamaguchi et al., “Construction of a cis-Cyclopropane via Reductive Radical Decarboxylation. Enantioselective Synthesis of cis- and trans-1-Arylpiperazyl-2-phenylcyclopropanes Designed as Antidopaminergic Agents,” J. Org. Chem., 2003, vol. 68, No. 24, pp. 9255-9262.
Zhang et al., “trans-1-[(2-Phenylcyclopropyl)methyl]-4-arylpiperazines: Mixed Dopamine D2/D4 Receptor Antagonists as Potential Antipsychotic Agents,” J. Med. Chem., 2000, vol. 43, pp. 3923-3932.
International Search Report issued for corresponding PCT/GB2008/050723 on Feb. 10, 2009.
Supplementary International Search Report issued for PCT/GB2008/050723 on Nov. 12, 2009.
English abstract of SU 1297727.
English abstract of UZ 3306.
English abstract of SU 1297727, (Mar. 25, 1984).
English abstract of UZ 3306, (Mar. 31, 2007).
Watanabe et al., “Investigation of the Bioactive Conformation of Histamine H3 Receptor Antagonists by the Cyclopropylic Strain-Based Conformational Restriction Strategy,” J. Med. Chem. 2010, vol. 53, pp. 3585-3593.

Affiliated with

Also associated with

Rating

Cyclopropyl amide derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclopropyl amide derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclopropyl amide derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4271612